Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence

Cocaine Dependence Clinical Trial

— BRAC  

Official title:

A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence (BRAC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01641159
• Other study ID #: CTN-0052
• Secondary ID: U10DA013732
• Status: Completed
• Phase: Phase 2
• First received: July 10, 2012
• Last updated: December 18, 2014
• Start date: August 2012
• Est. completion date: June 2013

Study information

• Verified date: December 2014
• Source: University of Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether or not buspirone is effective in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge.

Description:

The primary objective is to evaluate the efficacy of buspirone, relative to placebo, in preventing relapse in cocaine-dependent adults in inpatient/residential treatment who are planning to enter outpatient treatment upon inpatient/residential discharge. Secondary objectives include evaluating the impact of buspirone, relative to placebo, on other drug-abuse outcomes and on factors that may mediate buspirone's efficacy as a relapse-prevention treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. be 18 years of age or older

2. be able to understand the study, and having understood, provide written informed consent in English

3. meet DSM-IV-TR diagnostic criteria for current (within the last 12 months) dependence for cocaine, must self-report having used crack cocaine a minimum of four times in the 28 days prior to inpatient/residential admission, and must report that their typical pattern of use is at least once a week

4. have a willingness to comply with all study procedures and medication instructions

5. be enrolled in an inpatient/residential program at a participating CTP, scheduled to be in inpatient/residential treatment for 12-19 days when randomized, and planning to enroll in local outpatient treatment through the end of the active treatment phase (i.e., study week 15)

6. if female and of child bearing potential, agree to use one of the following methods of birth control:

• oral contraceptives

• contraceptive patch

• barrier (diaphragm or condom)

• intrauterine contraceptive system

• levonorgestrel implant

• medroxyprogesterone acetate contraceptive injection

• complete abstinence from sexual intercourse

• hormonal vaginal contraceptive ring

Exclusion Criteria:

1. meet DSM-IV-TR diagnostic criteria for current (within the last 12 months) opioid dependence

2. have a medical or psychiatric condition that, in the judgment of the study physician, would make study participation unsafe or which would make treatment compliance difficult. Medical conditions that may compromise participant safety or study conduct include, but are not limited to:

• AIDS according to the current CDC criteria for AIDS

• liver function tests greater than 3X upper limit of normal

• serum creatinine greater than 2 mg/dL

3. have a psychiatric disorder requiring continued treatment with a psychotropic medication

4. have a known or suspected hypersensitivity to buspirone

5. be pregnant or breastfeeding

6. have used any of the following medications within 14 days of randomization: monoamine oxidase (MAO) inhibitors such as phenelzine (Nardil), selegiline (Eldepryl), isocarboxazid (Marplan), or tranylcypromine (Parnate)

7. be taking any medications which, in the judgment of the study physician, may produce interactions with buspirone that are sufficiently dangerous so as to exclude the patient from participating in the study. Alternatively, the study physician, in consultation with the patient and his or her physician, may elect to withdraw the patient from the problem medications before randomization. Some of the possible interactions are discussed in section 8.8.

8. be anyone who, in the judgment of the investigator, would not be expected to complete the study protocol (e.g., due to relocation from the clinic area, probable incarceration, etc.)

9. be a significant suicidal/homicidal risk

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cocaine Dependence
• Cocaine-Related Disorders

Intervention

Drug:
• Buspirone
Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
• Placebo
Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.

Locations

Country	Name	City	State
United States	Morris Village/LRADAC	Columbia	South Carolina
United States	Maryhaven Inc	Columbus	Ohio
United States	Nexus Recovery Services	Dallas	Texas
United States	Gateway Community Services	Jacksonville	Florida
United States	Penn Presbyterian	Philadelphia	Pennsylvania
United States	Addiction Medicine Services	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
University of Cincinnati	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Winhusen T, Brady KT, Stitzer M, Woody G, Lindblad R, Kropp F, Brigham G, Liu D, Sparenborg S, Sharma G, Vanveldhuisen P, Adinoff B, Somoza E. Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world. Contemp Clin Trials. 2012 Sep;33(5):993-1002. doi: 10.1016/j.cct.2012.05.003. Epub 2012 May 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Days of Continuous Cocaine Abstinence	The primary outcome measure selected for the present two-stage protocol is the maximum days of continuous cocaine abstinence during study weeks 4-15. The Timeline Follow-back (TLFB) procedure (Sobell and Sobell, 1992; Fals-Stewart, 2000) will be used to assess the participants' self-reported use of substances for each day of the study. A rapid UDS system that screens for drugs of abuse will be used to analyze the urine samples.	study week 16	No
Secondary	Cocaine-use Days	Cocaine use days during days 22-105 as assessed by UDS and self-report combined with no imputation	study week 16	No